Clinical Trial Update: Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating EXPAREL (bupivacaine liposome injectable suspension) for adductor canal block in patients undergoing primary unilateral total kn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Knee Osteoarthritis

Drugs mentioned

• Exparel (liposomal bupivacaine)

Snippet

Sponsor: Pacira Pharmaceuticals, Inc | Conditions: Knee Osteoarthritis, Pain Management | Phase 3 | Status: COMPLETED | Results posted: 2024-10-24